Katharina Modelska

Katharina Modelska, MD, PhD, currently serves as the Senior Vice President of Clinical Development at Protagonist Therapeutics since September 2023, leading the clinical strategy for the product pipeline, particularly for Rusfertide (PTG-300). Previous experience includes roles such as Vice President of Clinical Development at FibroGen, where strategic leadership for Roxadustat clinical programs was provided, and Senior Director positions at Pfizer, Inc. and Medivation, Inc., overseeing major oncology trials including the PROSPER trial. Katharina Modelska has a robust background in clinical development across various companies, focusing on oncology and infectious diseases, complemented by academic qualifications from prestigious institutions, including a PhD from the University of Bern and an MD from Wroclaw Medical University.